Mark E Peeples

List of Publications by Year
in descending order

124 papers	7,469 citations	53660 45 h-index	60497 81 g-index
130 all docs	130 docs citations	130 times ranked	6261 citing authors

#	Article	IF	Citations
1	Respiratory Syncytial Virus (RSV)â€"Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. Journal of Infectious Diseases, 2022, 225, 1189-1196.	1.9	16
2	Severe Acute Respiratory Syndrome Coronavirus 2 RNAemia and Clinical Outcomes in Children With Coronavirus Disease 2019. Journal of Infectious Diseases, 2022, 225, 208-213.	1.9	2
3	SARS-CoV-2 spreads through cell-to-cell transmission. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	145
4	Severe SARS-CoV-2 disease in the context of a NF-Î°B2 loss-of-function pathogenic variant. Journal of Allergy and Clinical Immunology, 2021, 147, 532-544.e1.	1.5	25
5	A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque. Journal of Virology, 2021, 95, .	1.5	2
6	Respiratory Syncytial Virus (Pneumoviridae). , 2021, , 747-756.		0
7	Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS ONE, 2021, 16, e0246770.	1.1	3
8	Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. Journal of Virology, 2021, 95, .	1.5	4
9	A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
10	Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. Journal of Medicinal Chemistry, 2021, 64, 3658-3676.	2.9	18
11	The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines. PLoS Pathogens, 2021, 17, e1009469.	2.1	17
12	Nonsegmented Negative-Sense RNA Viruses Utilize <i>N</i> ⁶ -Methyladenosine (m) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	26
13	CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats. Journal of Virology, 2021, 95, e0001021.	1.5	13
14	Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. Stem Cell Reviews and Reports, 2021, 17, 2107-2119.	1.7	0
15	A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Journal of Virology, 2021, 95, e0059221.	1.5	11
16	Atopic Neutrophils Prevent Postviral Airway Disease. Journal of Immunology, 2021, 207, 2589-2597.	0.4	5
17	Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus. PLoS Pathogens, 2021, 17, e1010142.	2.1	12
18	Advanced Live Attenuated Vaccines for the Prevention of Respiratory Syncytial Virus Infections in Young Children. Journal of Infectious Diseases, 2020, 222, 4-6.	1.9	4

#	Article	IF	Citations
19	Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children. Journal of Infectious Diseases, 2020, 221, 501-503.	1.9	3
20	Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein. Journal of Virology, 2020, 94, .	1.5	3
21	In vitro 3D culture lung model from expanded primary cystic fibrosis human airway cells. Journal of Cystic Fibrosis, 2020, 19, 752-761.	0.3	14
22	Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection. Journal of Virology, 2020, 94, .	1.5	10
23	Upregulation of CD32 in T Cells from Infants with Severe Respiratory Syncytial Virus Disease: A New Costimulatory Pathway?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 133-136.	1.4	4
24	N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I. Nature Microbiology, 2020, 5, 584-598.	5.9	169
25	The journey to a respiratory syncytial virus vaccine. Annals of Allergy, Asthma and Immunology, 2020, 125, 36-46.	0.5	72
26	Immune profiles provide insights into respiratory syncytial virus disease severity in young children. Science Translational Medicine, 2020, 12, .	5.8	43
27	Viral N6-methyladenosine upregulates replication and pathogenesis of human respiratory syncytial virus. Nature Communications, 2019, 10, 4595.	5.8	64
28	Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats. Journal of the Royal Society Interface, 2019, 16, 20190389.	1.5	19
29	Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunology and Allergy Clinics of North America, 2019, 39, 321-334.	0.7	3
30	Respiratory Syncytial Virus Vaccines. Pediatric Infectious Disease Journal, 2019, 38, e266-e269.	1.1	15
31	Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Review of Clinical Immunology, 2019, 15, 49-58.	1.3	8
32	Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. Journal of Infectious Diseases, 2018, 217, 24-34.	1.9	76
33	A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine, 2018, 36, 3842-3852.	1.7	12
34	The psychoactive substance of cannabis Î”9-tetrahydrocannabinol (THC) negatively regulates CFTR in airway cells. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1988-1994.	1.1	6
35	A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nature Communications, 2018, 9, 3067.	5.8	65
36	Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F ₂ Subunit Are Critical for Its Fusion Activity. Journal of Virology, 2018, 92, .	1.5	9

#	Article	IF	Citations
37	Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2017, 216, 1398-1406.	1.9	92
38	Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine, 2017, 35, 496-502.	1.7	41
39	Efficient method for site-directed mutagenesis in large plasmids without subcloning. PLoS ONE, 2017, 12, e0177788.	1.1	8
40	Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology, 2016, 12, 87-93.	3.9	121
41	Preventing Cleavage of the Respiratory Syncytial Virus Attachment Protein in Vero Cells Rescues the Infectivity of Progeny Virus for Primary Human Airway Cultures. Journal of Virology, 2016, 90, 1311-1320.	1.5	11
42	Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathogens, 2015, 11, e1005318.	2.1	215
43	Prefusion Fâ€"specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science Translational Medicine, 2015, 7, 309ra162.	5.8	312
44	Roles of the Putative Integrin-Binding Motif of the Human Metapneumovirus Fusion (F) Protein in Cell-Cell Fusion, Viral Infectivity, and Pathogenesis. Journal of Virology, 2014, 88, 4338-4352.	1.5	42
45	Interstitial Lung Disease in a Child with Antisynthetase Syndrome. Lung, 2013, 191, 441-443.	1.4	4
46	Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins. Current Topics in Microbiology and Immunology, 2013, 372, 83-104.	0.7	205
47	Replication of Respiratory Syncytial Virus Is Inhibited by the Host Defense Molecule Viperin. Journal of Innate Immunity, 2013, 5, 60-71.	1.8	38
48	Cholesterol-Rich Microdomains as Docking Platforms for Respiratory Syncytial Virus in Normal Human Bronchial Epithelial Cells. Journal of Virology, 2012, 86, 1832-1843.	1.5	65
49	Cholesterol-Rich Microdomains as Docking Platforms for Respiratory Syncytial Virus in Normal Human Bronchial Epithelial Cells. Journal of Virology, 2012, 86, 5408-5408.	1.5	0
50	Plasticity and Virus Specificity of the Airway Epithelial Cell Immune Response during Respiratory Virus Infection. Journal of Virology, 2012, 86, 5422-5436.	1.5	176
51	Distinct and Overlapping Roles of Nipah Virus P Gene Products in Modulating the Human Endothelial Cell Antiviral Response. PLoS ONE, 2012, 7, e47790.	1.1	47
52	Targeting RSV with Vaccines and Small Molecule Drugs. Infectious Disorders - Drug Targets, 2012, 12, 110-128.	0.4	29
53	Soluble Respiratory Syncytial Virus Fusion Protein in the Fully Cleaved, Pretriggered State Is Triggered by Exposure to Low-Molarity Buffer. Journal of Virology, 2011, 85, 3968-3977.	1.5	56
54	A Respiratory Syncytial Virus Replicon That Is Noncytotoxic and Capable of Long-Term Foreign Gene Expression. Journal of Virology, 2011, 85, 4792-4801.	1.5	27

#	Article	IF	Citations
55	Respiratory Syncytial Virus Engineered To Express the Cystic Fibrosis Transmembrane Conductance Regulator Corrects the Bioelectric Phenotype of Human Cystic Fibrosis Airway Epithelium <i>In Vitro</i>. Journal of Virology, 2010, 84, 7770-7781.	1.5	27
56	Mapping the anatomy of respiratory syncytial virus infection of the upper airways in chinchillas (Chinchilla lanigera). Comparative Medicine, 2010, 60, 225-32.	0.4	9
57	Determination of the henipavirus phosphoprotein gene mRNA editing frequencies and detection of the C, V and W proteins of Nipah virus in virus-infected cells. Journal of General Virology, 2009, 90, 398-404.	1.3	67
58	Aetiology of influenza-like illness in adults includes parainfluenzavirus type 4. Journal of Medical Microbiology, 2009, 58, 408-413.	0.7	35
59	Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on Glycosaminoglycans. Journal of Virology, 2009, 83, 10710-10718.	1.5	88
60	Respiratory syncytial virus-induced dysregulation of expression of a mucosal Î²-defensin augments colonization of the upper airway by non-typeable<i>Haemophilus influenzae</i>. Cellular Microbiology, 2009, 11, 1399-1408.	1.1	76
61	Interaction Between Respiratory Syncytial Virus and Glycosaminoglycans, Including Heparan Sulfate. Methods in Molecular Biology, 2007, 379, 15-34.	0.4	41
62	Differential Response of Dendritic Cells to Human Metapneumovirus and Respiratory Syncytial Virus. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 320-329.	1.4	171
63	Respiratory Syncytial Virus Infection Reduces Î²2-Adrenergic Responses in Human Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 559-564.	1.4	27
64	Requirements for the Assembly and Release of Newcastle Disease Virus-Like Particles. Journal of Virology, 2006, 80, 11062-11073.	1.5	155
65	Integrity of Membrane Lipid Rafts Is Necessary for the Ordered Assembly and Release of Infectious Newcastle Disease Virus Particles. Journal of Virology, 2006, 80, 10652-10662.	1.5	72
66	Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway Epithelium. Journal of Virology, 2005, 79, 1113-1124.	1.5	259
67	RhoA Signaling Is Required for Respiratory Syncytial Virus-Induced Syncytium Formation and Filamentous Virion Morphology. Journal of Virology, 2005, 79, 5326-5336.	1.5	104
68	Evolution of Vaccinia Virus-Specific CD8+ Cytotoxic T-Lymphocyte Responses in Primary Vaccinees and Revaccinees. Vaccine Journal, 2004, 11, 758-761.	2.6	7
69	Protein Kinase C-Î± Activity Is Required for Respiratory Syncytial Virus Fusion to Human Bronchial Epithelial Cells. Journal of Virology, 2004, 78, 13717-13726.	1.5	30
70	ERK-1/2 activity is required for efficient RSV infection. FEBS Letters, 2004, 559, 33-38.	1.3	37
71	Completion of trimeric hairpin formation of influenza virus hemagglutinin promotes fusion pore opening and enlargement. Virology, 2003, 316, 234-244.	1.1	39
72	Neuraminidase treatment of respiratory syncytial virus-infected cells or virions, but not target cells, enhances cellâ€"cell fusion and infection. Virology, 2003, 313, 33-43.	1.1	25

#	Article	IF	Citations
73	Respiratory Syncytial Virus Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and without Obvious Cytopathology. Journal of Virology, 2002, 76, 5654-5666.	1.5	489
74	Mapping the Transcription and Replication Promoters of Respiratory Syncytial Virus. Journal of Virology, 2002, 76, 1663-1672.	1.5	68
75	Respiratory Syncytial Virus with the Fusion Protein as Its only Viral Glycoprotein Is Less Dependent on Cellular Glycosaminoglycans for Attachment than Complete Virus. Virology, 2002, 294, 296-304.	1.1	107
76	Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Letters, 2001, 172, 27-36.	3.2	148
77	RhoA Is Activated During Respiratory Syncytial Virus Infection. Virology, 2001, 283, 188-196.	1.1	57
78	Synergistic Effects of Gene-End Signal Mutations and the M2-1 Protein on Transcription Termination by Respiratory Syncytial Virus. Virology, 2001, 288, 295-307.	1.1	37
79	Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene. Journal of Virology, 2001, 75, 6825-6834.	1.5	233
80	Iduronic Acid-Containing Glycosaminoglycans on Target Cells Are Required for Efficient Respiratory Syncytial Virus Infection. Virology, 2000, 271, 264-275.	1.1	203
81	Mutations in the 5â€² Trailer Region of a Respiratory Syncytial Virus Minigenome Which Limit RNA Replication to One Step. Journal of Virology, 2000, 74, 146-155.	1.5	51
82	Functional Analysis of the Genomic and Antigenomic Promoters of Human Respiratory Syncytial Virus. Journal of Virology, 2000, 74, 6006-6014.	1.5	49
83	Glycosaminoglycan Sulfation Requirements for Respiratory Syncytial Virus Infection. Journal of Virology, 2000, 74, 10508-10513.	1.5	268
84	Detection and Quantitation of Human Respiratory Syncytial Virus (RSV) Using Minigenome cDNA and a Sindbis Virus Replicon: A Prototype Assay for Negative-Strand RNA Viruses. Virology, 1998, 251, 198-205.	1.1	20
85	The NS1 Protein of Human Respiratory Syncytial Virus Is a Potent Inhibitor of Minigenome Transcription and RNA Replication. Journal of Virology, 1998, 72, 1452-1461.	1.5	93
86	Increased Expression of the N Protein of Respiratory Syncytial Virus Stimulates Minigenome Replication but Does Not Alter the Balance between the Synthesis of mRNA and Antigenome. Virology, 1997, 236, 188-201.	1.1	104
87	An Altered Form of Apolipoprotein H Binds Hepatitis B Virus Surface Antigen Most Efficiently. Virology, 1996, 217, 58-66.	1.1	28
88	Intracellular Maturation of the Newcastle Disease Virus Fusion Protein Is Affected by Strain Differences in the Predicted Amphipathic Î±-Helix Adjacent to the Fusion Domain. Virology, 1995, 208, 827-831.	1.1	1
89	Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.. Journal of Experimental Medicine, 1995, 182, 501-509.	4.2	244
90	Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy. Journal of the National Cancer Institute, 1994, 86, 1228-1233.	3.0	117

#	Article	IF	Citations
91	The hepatitis B virus receptor: Book'em, Dano?. Hepatology, 1994, 20, 1364-1366.	3.6	1
92	Hepatitis B virus surface antigen binds to apolipoprotein H. Journal of Virology, 1994, 68, 2415-2424.	1.5	86
93	The Attachment Function of the Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein Can Be Separated from Fusion Promotion by Mutation. Virology, 1993, 193, 717-726.	1.1	129
94	The Matrix Protein of Newcastle Disease Virus Localizes to the Nucleus via a Bipartite Nuclear Localization Signal. Virology, 1993, 195, 596-607.	1.1	73
95	Characterization and Acute-Phase Modulation of Canine Apolipoprotein H (Î²2-Glycoprotein 1). Biochemical and Biophysical Research Communications, 1993, 191, 1288-1293.	1.0	22
96	Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. Journal of Pediatric Surgery, 1993, 28, 1221-1226.	0.8	9
97	Newcastle disease virus selectively kills human tumor cells. Journal of Surgical Research, 1992, 52, 448-453.	0.8	210
98	Nuclear entry and nucleolar localization of the Newcastle disease virus (NDV) matrix protein occur early in infection and do not require other NDV proteins. Journal of Virology, 1992, 66, 3263-3269.	1.5	71
99	Intracellular processing of the paramyxovirus F protein: critical role of the predicted amphipathic alpha helix adjacent to the fusion domain. Journal of Virology, 1992, 66, 4161-4169.	1.5	30
100	Cranial nerve involvement with Lyme borreliosis demonstrated by magnetic resonance imaging. Neurology, 1992, 42, 671-671.	1.5	34
101	Nucleotide sequence and expression of the human gene encoding apolipoprotein H (Î²2-glycoprotein I). Gene, 1991, 108, 293-298.	1.0	82
102	Paramyxovirus M Proteins. , 1991, , 427-456.		48
103	Isolation and characterization of Borrelia burgdorferi from Illinois Ixodes dammini. Journal of Clinical Microbiology, 1991, 29, 1732-1734.	1.8	24
104	Kinetics of virus-induced hemolysis measured for single erythrocytes. Virology, 1990, 174, 593-598.	1.1	5
105	Physiology and function of the vero cell receptor for the hepatitis B virus small S protein. Virology, 1990, 177, 332-338.	1.1	6
106	Detection of Antibodies in Late Lyme Disease. Journal of Infectious Diseases, 1990, 161, 1034-1035.	1.9	6
107	Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region. Journal of Virology, 1989, 63, 1981-1988.	1.5	149
108	Association of soluble matrix protein of newcastle disease virus with liposomes is independent of ionic conditions. Virology, 1988, 166, 123-132.	1.1	35

#	Article	IF	Citations
109	The vero cell receptor for the hepatitis B virus small S protein is a sialoglycoprotein. Virology, 1988, 163, 629-634.	1.1	17
110	Differential detergent treatment allows immunofluorescent localization of the Newcastle disease virus matrix protein within the nucleus of infected cells. Virology, 1988, 162, 255-259.	1.1	45
111	Temperature-sensitive mutants of Newcastle disease virus altered in HN glycoprotein size, stability, or antigenic maturity. Virology, 1988, 164, 284-289.	1.1	6
112	Newcastle Disease Virus Replication. Developments in Veterinary Virology, 1988, , 45-78.	0.3	11
113	Strain variation and nuclear association of Newcastle disease virus matrix protein. Journal of Virology, 1988, 62, 586-593.	1.5	32
114	Conformational change in a viral glycoprotein during maturation due to disulfide bond disruption.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 1020-1024.	3.3	48
115	A cultured cell receptor for the small S protein of hepatitis B virus. Virology, 1987, 160, 135-142.	1.1	15
116	Mutation in the matrix protein of Newcastle disease virus can result in decreased fusion glycoprotein incorporation into particles and decreased infectivity. Journal of Virology, 1984, 51, 81-90.	1.5	46
117	Thermostabilities of Virion Activities of Newcastle Disease Virus: Evidence that the Temperature-Sensitive Mutants in Complementation Groups B, BC, and C Have Altered HN Proteins. Journal of Virology, 1983, 45, 18-26.	1.5	11
118	UV irradiation analysis of complementation between, and replication of, RNA-negative temperature-sensitive mutants of Newcastle disease virus. Journal of Virology, 1982, 41, 965-973.	1.5	27
119	Virion functions of RNA+ temperature-sensitive mutants of Newcastle disease virus. Journal of Virology, 1982, 42, 440-446.	1.5	17
120	RNA synthesis by Newcastle disease virus temperature-sensitive mutants in two RNA-negative complementation groups. Journal of Virology, 1982, 42, 996-1006.	1.5	13
121	Characteristics of a persistent respiratory syncytial virus infection in HeLa cells. Virology, 1981, 113, 141-149.	1.1	4
122	Metabolic Requirements for the Maturation of Respiratory Syncytial Virus. Journal of General Virology, 1980, 50, 81-88.	1.3	7
123	Respiratory syncytial virus polypeptides: Their location in the virion. Virology, 1979, 95, 137-145.	1.1	96
124	Effect of Respiratory Syncytial Virus Infection of HeLa-Cell Macromolecular Synthesis. Journal of General Virology, 1977, 37, 53-63.	1.3	17